preclinical_heavy
Preclinical evidence exceeds central human evidence. Interpret translational relevance cautiously.
supportedtophigh inflation risk
Akkermansia muciniphila
obesity
Akkermansia muciniphila has meaningful literature visibility in obesity, but the current evidence mix suggests a substantial risk of overclaiming.
Akkermansia muciniphila shows a moderate evidence base in obesity, with multiple central papers and additional supporting literature.
akkermansia_muciniphila
Credibility score
51
Human translation
1/5
Reproducibility
5/5
Novelty
2/5
Actionability
2/5
Credibility 51Human translation 1/5Reproducibility 5/5Novelty 2/5Actionability 2/5
Why this scores the way it does
- moderate central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- preclinical evidence outweighs human evidence
- review density exceeds central evidence depth
Internal review flags
2 flagsreview_heavy
Review literature is very dense relative to primary central evidence.
Primary central evidence
8 papersCross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity.
2013Proceedings of the National Academy of Sciences of the United States of America
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions.
2018Experimental & molecular medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The Gut Microbiota during a Behavioral Weight Loss Intervention.
2021Nutrients
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The evolution and competitive strategies of Akkermansia muciniphila in gut.
2022Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity.
2024Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Multi-omics insights into the microbiota-gut-brain axis and cognitive improvement post-bariatric surgery.
2024Journal of translational medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota-derived 4-hydroxyphenylacetic acid from resveratrol supplementation prevents obesity through SIRT1 signaling activation.
2025Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Comparing the effects of yogurt containing Akkermansia muciniphilia postbiotic with yogurt containing Lactobacillus rhamnosus postbiotic on body composition, biochemical indices, appetite, and depression scores in overweight or obese adults: A randomized, double-blind, controlled clinical trial.
2025Clinical nutrition ESPEN
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
20 papersAkkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology.
2016Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice.
2017Nature medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study.
2019Nature medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice.
2019Nature medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Akkermansia muciniphila reduces Porphyromonas gingivalis-induced inflammation and periodontal bone destruction.
2020Journal of clinical periodontology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism.
2020The British journal of nutrition
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Genotypic and Phenotypic Diversity among Human Isolates of Akkermansia muciniphila.
2021mBio
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis.
2021Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
High-fat-diet-associated intestinal microbiota exacerbates psoriasis-like inflammation by enhancing systemic γδ T cell IL-17 production.
2023Cell reports
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Outer Membrane Vesicles Released from Garlic Exosome-like Nanoparticles (GaELNs) Train Gut Bacteria that Reverses Type 2 Diabetes via the Gut-Brain Axis.
2024Small (Weinheim an der Bergstrasse, Germany)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet.
2024European journal of pharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
An orally active carbon monoxide-releasing molecule enhances beneficial gut microbial species to combat obesity in mice.
2024Redox biology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Effects of Prevotella copri on insulin, gut microbiota and bile acids.
2024Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Multiomics reveals the ameliorating effect and underlying mechanism of aqueous extracts of polygonatum sibiricum rhizome on obesity and liver fat accumulation in high-fat diet-fed mice.
2024Phytomedicine : international journal of phytotherapy and phytopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Dietary inulin ameliorates obesity-induced severe acute pancreatitis via gut-pancreas axis.
2024Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut.
2025Cell metabolism
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Quercetin-Driven Akkermansia Muciniphila Alleviates Obesity by Modulating Bile Acid Metabolism via an ILA/m6A/CYP8B1 Signaling.
2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
GLP-1RAs attenuated obesity and reversed leptin resistance partly via activating the microbiome-derived inosine/A2A pathway.
2025Acta pharmaceutica Sinica. B
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Pasteurized Akkermansia muciniphila ameliorates preeclampsia via inhibiting mitochondrial dysfunction-mediated placental apoptosis in vivo and in vitro.
2025Free radical biology & medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Akkermansia muciniphila modulates intestinal mucus composition to counteract high-fat diet-induced obesity in mice.
2026Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
28 papersThe human gut microbiota: Metabolism and perspective in obesity.
2018Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Human gut microbiome: hopes, threats and promises.
2018Gut
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiome: Profound Implications for Diet and Disease.
2019Nutrients
Relevant review or meta-analysis for the signal-disease area.
The Bacterium Akkermansia muciniphila: A Sentinel for Gut Permeability and Its Relevance to HIV-Related Inflammation.
2020Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
Mucus barrier, mucins and gut microbiota: the expected slimy partners?
2020Gut
Relevant review or meta-analysis for the signal-disease area.
The Emerging Biotherapeutic Agent: Akkermansia.
2022Indian journal of microbiology
Relevant review or meta-analysis for the signal-disease area.
Human microbiome and metabolic health: An overview of systematic reviews.
2022Obesity reviews : an official journal of the International Association for the Study of Obesity
Relevant review or meta-analysis for the signal-disease area.
Gut microbiome and health: mechanistic insights.
2022Gut
Relevant review or meta-analysis for the signal-disease area.
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms.
2022Nature reviews. Gastroenterology & hepatology
Relevant review or meta-analysis for the signal-disease area.
Akkermansia muciniphila and Gut Immune System: A Good Friendship That Attenuates Inflammatory Bowel Disease, Obesity, and Diabetes.
2022Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs.
2022The American journal of clinical nutrition
Relevant review or meta-analysis for the signal-disease area.
Physiological benefits of Akkermansia muciniphila under high-altitude hypoxia.
2023Applied microbiology and biotechnology
Relevant review or meta-analysis for the signal-disease area.
Akkermansia muciniphila as a Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression: A Role Mediated by Gut-Liver-Brain Axes?
2023International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives.
2023International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Akkermansia muciniphila: A potential target and pending issues for oncotherapy.
2023Pharmacological research
Relevant review or meta-analysis for the signal-disease area.
Meta-analysis reveals obesity associated gut microbial alteration patterns and reproducible contributors of functional shift.
2024Gut microbes
Relevant review or meta-analysis for the signal-disease area.
The influence of Akkermansia muciniphila on intestinal barrier function.
2024Gut pathogens
Relevant review or meta-analysis for the signal-disease area.
Akkermansia muciniphila: A promising probiotic against inflammation and metabolic disorders.
2024Virulence
Relevant review or meta-analysis for the signal-disease area.
Akkermansia in the gastrointestinal tract as a modifier of human health.
2024Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Akkermansia muciniphila - impact on the cardiovascular risk, the intestine inflammation and obesity.
2024Acta biochimica Polonica
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota: An Important Participant in Childhood Obesity.
2025Advances in nutrition (Bethesda, Md.)
Relevant review or meta-analysis for the signal-disease area.
Health Effects and Therapeutic Potential of the Gut Microbe Akkermansia muciniphila.
2025Nutrients
Relevant review or meta-analysis for the signal-disease area.
Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review.
2025Nutrients
Relevant review or meta-analysis for the signal-disease area.
[Gut Microbiota and Obesity].
2023The Korean journal of helicobacter and upper gastrointestinal research
Relevant review or meta-analysis for the signal-disease area.
The Role of Akkermansia muciniphila in Disease Regulation.
2025Probiotics and antimicrobial proteins
Relevant review or meta-analysis for the signal-disease area.
Akkermansia muciniphila: A key player in gut microbiota-based disease modulation.
2025Microbiological research
Relevant review or meta-analysis for the signal-disease area.
Akkermansia muciniphila in neurological disorders: mechanisms and therapeutic potential via the gut-brain axis.
2025Frontiers in neuroscience
Relevant review or meta-analysis for the signal-disease area.
Obesity and Cancer: A Translational Science Review.
2026JAMA
Relevant review or meta-analysis for the signal-disease area.